VA Formulary Inclusion: The Inflection Point
The formal listing of ActiPatch and RecoveryRx in the VA National Formulary is more than regulatory housekeeping—it’s the launchpad for systemic transformation. With this single inclusion:
BIEL’s devices become standard-of-care for millions of veterans
VA clinicians prescribe without restrictions or special authorizations
Accessibility and credibility skyrocket, driving adoption across federal healthcare
Real-world outcomes fuel data collection for further validation and expansion
This milestone turns the VA into a clinical proving ground—and an equity accelerant.
Legislative Tailwinds: The NOPAIN for Veterans Act
This bipartisan legislation mandates:
VA inclusion of FDA-cleared non-opioid therapies covered by Medicare
Full reimbursement for veterans—no out-of-pocket costs
Prescribing freedom for VA physicians
Built on the foundation of the NOPAIN Act (2022), the 2024 extension ensures safe, drug-free pain management is not optional—it’s required. For BIEL, it’s legislative momentum backing their mission.
Partner Wealth Creation: VLMS & Viant’s Strategic Upside
As operational partners, VLMS Global Healthcare and Viant Medical do more than deliver results—they’re accumulating equity in a publicly traded company they’re helping scale. Their roles become financial levers:
1. Contributors → Co-Owners
Every billing expansion (VLMS) and every manufacturing rollout (Viant) drives BIEL’s valuation
Strategic accumulation of BIEL shares means owning the upside, without disrupting private structures
2. Equity as Incentive
Business wins become portfolio wins—every new market entry lifts BIEL’s PPS
Equity turns execution into long-term financial reward
3. Leverage Without Dilution
Public shares offer voting influence without corporate restructuring
Liquidity and governance optionality without sacrificing autonomy
4. Shared Success & Synergy
Unified focus: commercialization, clinical growth, tech innovation
Insider ownership inspires investor confidence and accelerates capital access
Why It All Matters
The VA formulary inclusion legitimizes BIEL’s PEMF devices at a national level. The legislative push ensures ongoing support. And the partner equity strategy guarantees that the very organizations driving BIEL’s success are financially vested in its future.
In short: ✅ Access is unlocked ✅ Revenue is predictable ✅ Partners are invested ✅ Growth is aligned
This is not just a clinical opportunity. It’s a healthcare wealth engine—where healing pain also builds prosperity.
The formal listing of ActiPatch and RecoveryRx in the VA National Formulary is more than regulatory housekeeping—it’s the launchpad for systemic transformation. With this single inclusion:
BIEL’s devices become standard-of-care for millions of veterans
VA clinicians prescribe without restrictions or special authorizations
Accessibility and credibility skyrocket, driving adoption across federal healthcare
Real-world outcomes fuel data collection for further validation and expansion
This milestone turns the VA into a clinical proving ground—and an equity accelerant.
Legislative Tailwinds: The NOPAIN for Veterans Act
This bipartisan legislation mandates:
VA inclusion of FDA-cleared non-opioid therapies covered by Medicare
Full reimbursement for veterans—no out-of-pocket costs
Prescribing freedom for VA physicians
Built on the foundation of the NOPAIN Act (2022), the 2024 extension ensures safe, drug-free pain management is not optional—it’s required. For BIEL, it’s legislative momentum backing their mission.
Partner Wealth Creation: VLMS & Viant’s Strategic Upside
As operational partners, VLMS Global Healthcare and Viant Medical do more than deliver results—they’re accumulating equity in a publicly traded company they’re helping scale. Their roles become financial levers:
1. Contributors → Co-Owners
Every billing expansion (VLMS) and every manufacturing rollout (Viant) drives BIEL’s valuation
Strategic accumulation of BIEL shares means owning the upside, without disrupting private structures
2. Equity as Incentive
Business wins become portfolio wins—every new market entry lifts BIEL’s PPS
Equity turns execution into long-term financial reward
3. Leverage Without Dilution
Public shares offer voting influence without corporate restructuring
Liquidity and governance optionality without sacrificing autonomy
4. Shared Success & Synergy
Unified focus: commercialization, clinical growth, tech innovation
Insider ownership inspires investor confidence and accelerates capital access
Why It All Matters
The VA formulary inclusion legitimizes BIEL’s PEMF devices at a national level. The legislative push ensures ongoing support. And the partner equity strategy guarantees that the very organizations driving BIEL’s success are financially vested in its future.
In short: ✅ Access is unlocked ✅ Revenue is predictable ✅ Partners are invested ✅ Growth is aligned
This is not just a clinical opportunity. It’s a healthcare wealth engine—where healing pain also builds prosperity.
1
